Elevai Labs Inc ELAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELAB is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- $0.63
- Day Range
- $0.63–0.65
- 52-Week Range
- $0.57–4.24
- Bid/Ask
- $0.63 / $0.65
- Market Cap
- $10.92 Mil
- Volume/Avg
- 75,608 / 366,911
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Elevai Labs Inc is a California-based physician-dispensed skincare company with a focus on modernizing aesthetic skincare. It has commercialized ELEVAI Exosomes a next-generation, patent-pending technology used in its ELEVAI flagship products.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 18
- Website
- https://www.elevailabs.com
Valuation
|
Metric
|
ELAB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.86 |
Price/Sales | 3.96 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ELAB
|
|---|---|
Quick Ratio | 2.59 |
Current Ratio | 3.79 |
Interest Coverage | −219.59 |
Quick Ratio
ELAB
Profitability
|
Metric
|
ELAB
|
|---|---|
Return on Assets (Normalized) | −126.52% |
Return on Equity (Normalized) | −270.98% |
Return on Invested Capital (Normalized) | −224.99% |
Return on Assets
ELAB
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Drtzxvnyq | Wzcm | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Fclzwsw | Pqwkr | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cvyqblfg | Ytlch | $107.6 Bil | |
MRNA
| Moderna Inc | Lxdvcdjq | Wfsfw | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Hmpghphg | Tyn | $22.2 Bil | |
ARGX
| argenx SE ADR | Mqhrhjpvk | Pvhb | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Zvdgrwzz | Bncncx | $19.0 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pgysqdtyq | Zcndds | $15.1 Bil | |
INCY
| Incyte Corp | Yvrqgjvm | Zdzjc | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rbkvtvjhyl | Gqztjjd | $12.7 Bil |